Biosimilars

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.

Doug Long, vice president of industry relations at IMS Health, discusses if health care providers will be hesitant to prescribe biosimilars.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses the projected ramifications from the launch of biosimilars in the United States.

Cancer therapy filgrastim-sndz (Zarxio) was initially approved on March 6, 2015.

Policy may mitigate inaccurate perceptions of safety and efficacy for biological products.

The FDA has proposed adding a 4-letter suffix to the names of biosimilars to distinguish them from their biologic counterparts.

Study estimates United States is wasting $45 million every month that biosimilar Zarxio is not on the market.

Top stories of the week on Specialty Pharmacy Times.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses the potential impact of biosimilars on the specialty drug market.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Pharmacists will need to evaluate several new factors when selecting and dispensing products.

With biosimilars set to enter the US health care market, pharmacists will soon have new factors to consider when selecting and dispensing products.

Top stories of the week on Specialty Pharmacy Times from July 13 to July 17.

Pfizer executive discusses the present and future of biosimilars.

CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how specialty pharmacies can best manage the rising cost of specialty drugs to improve outcomes for patients.

There are currently more than 600 trials of biosimilars ongoing.

Fred Eckel, RPh, MS, Editor-in-Chief of Pharmacy Times, reflects on how pharmacists will be affected by FDA approvals of biosimilars.

The first biosimilar product in the United States has been approved, and the time is now for specialty pharmacists to become familiar with the use and regulation of these drugs.

Biosimilars are finally a reality in the US drug market, but a report warns regulatory decisions may limit future savings from the drugs.

FDA approves Zarxio for the same indications as Neupogen.

New recommendations involve drugs containing several adapalene formulations.

Raulo Frear, PharmD, general manager of OmedaRx, discusses the ramifications of biosimilars hitting the US market.

Filgrastim is indicated to decrease the incidence of infection in patients with non-myeloid malignancies who also are receiving myelosuppressive anti-cancer drugs.

The Academy of Managed Care Pharmacy today supported the U.S. Food and Drug Administration's use of "an expedited approval process" for biosimilars to encourage the development of both new and more affordable treatments for such serious conditions as cancer, multiple sclerosis and rheumatoid arthritis.